Sovaldi (sofosbuvir) licensee Cipla intends to keep a ''very keen eye'' on the product's affordability and hopes, going forward, to pare prices below Gilead Sciences' reported $900 offer in Egypt for a course of treatment with the product.
''Without getting into details of pricing strategies, what I can say is that Cipla is, over the medium term, going...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?